Escherichia coli

Overview

Escherichia coli is a Gram-negative, rod-shaped bacterium of the family Enterobacteriaceae and a normal inhabitant of the lower intestinal tract of humans and other warm-blooded animals. It is a facultative anaerobe that grows rapidly on simple defined media, and its small, fully sequenced genome and extensive genetic toolkit have made it the reference prokaryotic model organism for molecular biology. Most strains are harmless commensals, while defined lineages — including enterohemorrhagic E. coli O157:H7 and extraintestinal pathogenic strains — cause diarrheal illness, urinary tract infection, neonatal meningitis, and sepsis. Foodborne and wound-associated E. coli is a routine benchmark Gram-negative organism in antimicrobial testing, typically evaluated alongside Staphylococcus aureus, Pseudomonas aeruginosa, and Candida albicans to distinguish activity across the Gram-negative outer membrane, the Gram-positive cell wall, and the fungal envelope.

The outer membrane of E. coli, with its lipopolysaccharide leaflet and selective porins, restricts entry of hydrophobic and large-molecule antimicrobials and underlies much of the organism's intrinsic resistance; acquired β-lactamases, including carbapenemases such as NDM-5, extend that resistance to front-line drugs. E. coli also forms biofilms in which an extracellular polymeric matrix reduces antibiotic penetration and metabolic activity, a phenotype targeted by plant-derived agents such as carvacrol and other essential-oil constituents, by polyphenols including rutin, kaempferol, curcumin, and resveratrol, and by metal and metal-oxide nanoparticles such as silver, zinc oxide, and selenium nanoparticles. Many of these agents act at least in part by generating reactive oxygen species and hydrogen peroxide that impose oxidative stress and compromise membrane integrity, effects often measured together with antioxidant and glutathione-related readouts. In parallel, E. coli remains a principal engineering chassis: serine-integrase and CRISPR-Cas systems, including CRISPR-Cas12a, permit precise, iterative genome modification, supporting recombinant protein expression in strains such as BL21(DE3) and metabolic-engineering routes to amino acid, nucleotides, glycosides, and related compounds, as well as its use in biosensor and synthetic-biology platforms.

Recent Publications Summary (latest 30 papers)

Recent research has extensively explored natural and synthetic antimicrobial agents against Escherichia coli, reflecting the pathogen's role in foodborne illness and clinical infections. Plant-derived compounds, particularly essential oils and leaf extracts, demonstrated significant antibacterial activity. Goldenberry juice reduced E. coli growth by 1–3 log CFU/mL 42463768Jul, while guava leaf aqueous extract exhibited minimum inhibitory concentrations of 800 μg/mL 42375034Jun. Thyme essential oil was particularly effective, achieving 7 log reductions against E. coli biofilms at twice the minimum inhibitory concentration 42332877Jun, and anise essential oil encapsulated in chitosan nanocarriers showed minimum inhibitory concentrations of 45–50 μg/mL 42143655May. Ocimum basilicum Genovese variety displayed stronger antibacterial activity against E. coli compared to its basilicum counterpart 42185519May, while lemon peel extract obtained via supercritical CO₂ extraction exhibited antimicrobial activity against E. coli 42108813May.

Nanoparticle-based approaches have emerged as potent alternatives for combating E. coli infections. Sparfloxacin-loaded solid lipid nanoparticle demonstrated two-fold higher antibacterial potency against E. coli compared to free drug 42437591Jul. silver nanoparticles synthesized using green tea extract showed the fastest bactericidal kinetics, achieving >10 log CFU/mL reduction within 2–6 hours against E. coli isolated from diabetic foot ulcers 42297939Jun. selenium nanoparticles biosynthesized from olive leaf extract exhibited antimicrobial efficacy against E. coli and reduced biofilm formation 42143081May, while magnesium oxide nanoparticles generated from Sonneratia ovata leaf extract showed promise as an antimicrobial agent 42289157Jun. Magnesene nanosheets induced localized magnesium overload that disrupted E. coli membrane integrity and bacterial transport functions 42126348May, and cysteine-derived carbon dots achieved >95% bacterial eradication of E. coli at 62.5 μg/mL under visible-light illumination through photocatalytic generation of reactive oxygen species 42113536May.

Advanced delivery systems and therapeutic formulations have enhanced antimicrobial efficacy against E. coli. Photothermal-responsive hydrogels containing black phosphorus-gold nanosheets demonstrated significant antibacterial effects against high-concentration E. coli suspensions (10⁷ CFU·mL⁻¹) under 808 nm near-infrared light 42257624Jun. Core-shell microneedles integrating chondroitin sulfate and chito-oligosaccharide achieved 98.8% antibacterial inhibition against E. coli with programmable, stage-specific release kinetics 42235776Jun. High-amylose maize starch hydrogels encapsulating thyme essential oil produced inhibition zones of 20 mm against E. coli with diffusion-controlled, Higuchi-model kinetics 42219099May. Dissolving microneedles co-loaded with deferoxamine-anchored Ti₃C₂Tₓ MXene nanosheets enabled deep intradermal delivery and potent photothermal antibacterial effects against E. coli in polymicrobial-infected wound models 42119861May. Hyaluronate-coated novasomes and spray-dried co-encapsulated formulations showed strong antibacterial activity against E. coli in disk diffusion and minimum inhibitory concentration assays 42303711Jun42302970Jun.

Molecular and genetic studies have characterized E. coli mechanisms of antimicrobial resistance and infection. Detection methods coupling thermal-optimized PCR with CRISPR-Cas12a rapidly identified E. coli isolates harboring the blaOXA-1 β-lactamase resistance gene within 50 minutes 42139236May. CRISPR interference systems demonstrated variable repression efficiency across laboratory and clinical E. coli strains, with dCas9 and dCas12a variants showing strain-specific toxicity and gene silencing effects 42068556May. Synthetic cyclodipeptides derived through hydrazine-mediated cyclization exhibited antibacterial activity against E. coli, with four newly synthesized compounds demonstrating inhibitory capacity 42065477May, while novel 5-amino-4-cyano-1,3-oxazole derivatives showed minimum inhibitory concentrations of 8–64 μg/mL against colistin-resistant E. coli isolates 42063275May. Clinical investigation documented a rare case of meningoencephalitis caused by E. coli in an immunocompetent adult, highlighting the pathogen's capacity to cause severe central nervous system infection 42126990May, and a bilayer hydrogel colorimetric sensor array achieved ultrasensitive detection of E. coli O157:H7 as a spoilage marker, enabling food freshness monitoring 42402202Jul.

What Changes, What Holds

1. Natural products continue to expand the antibacterial toolkit against E. coli
REINFORCES Plant extracts and essential oils add more examples to the already established pattern that E. coli is a routine target for screening of natural antimicrobials, including biofilm-active agents. The new work does not alter the baseline account of intrinsic resistance, outer-membrane barriers, or the use of these compounds as candidate antibacterials; it mainly broadens the catalog of active botanicals and formulations. 42463768Jul42332877Jun

2. Nanomaterials remain a productive way to intensify activity against E. coli
REINFORCES These studies fit the existing view that nanoparticles can overcome some of E. coli’s permeability and biofilm defenses, often through membrane damage and oxidative stress. The new results sharpen that theme with several delivery and synthesis variants, but they do not displace the baseline mechanism or introduce a new biological role for the organism. 42437591Jul42113536May

3. Formulation engineering can materially improve anti-E. coli performance
REINFORCES Advanced carriers, hydrogels, and microneedle systems extend the baseline’s point that E. coli is a standard benchmark for antimicrobial testing, especially in wound and delivery contexts. What changes here is not the organism’s biology but the practical lesson that local release, photothermal activation, and staged delivery can raise apparent efficacy against it. 42257624Jun42119861May

4. Rapid resistance detection and strain-specific gene control are becoming practical E. coli tools
METHOD Thermal-optimized PCR coupled to CRISPR-Cas12a and CRISPR interference systems changes how E. coli is detected and manipulated, not what the organism is known to be. The work strengthens the baseline’s statement that CRISPR-based systems support precise genome work in E. coli, while also showing that repression efficiency and toxicity vary by strain. 42139236May42068556May

Overview update candidates: additional natural-product examples and biofilm inhibition; none beyond more examples of nanoparticle-mediated antibacterial activity; these are delivery-platform refinements rather than new biology; improved rapid detection of resistance genes and strain-dependent CRISPR interference behavior.